Nano innovation could mean eye injections are a thing of the past

Mar 05, 2014

Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough for the millions worldwide suffering from age-related macular degeneration (AMD) and other eye disorders.

1 in 5 people over 75 have AMD with well-known sufferers including actress Dame Judi Dench and author Stephen King. The research findings are significant due to growing patient numbers and an increasing demand for the eye injections that halt the progression of the disease.

The research, demonstrated in animal models and published today in nanotechnology journal Small, demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the AMD drug Avastin and deliver significant concentrations to the back of the eye. Lead author Professor Francesca Cordeiro (UCL Institute of Ophthalmology) said: "The development of that can be safely and effectively used in patients would be a magic bullet – a huge breakthrough in the treatment of AMD and other debilitating eye disorders.

"The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months. It's impossible to exaggerate the relief patients would feel at not having to experience injections into their eyes."

The NHS is currently overburdened with patients who need repeat eye injections and the numbers are set to rise exponentially over the next ten years. Demand is so high that injections are difficult to administer, time-consuming and very expensive. The treatment also carries a risk of infection and bleeding, increased by the frequency of recurrent injections into the eyes. In the USA, well over one million ocular injections were given in 2010. In the UK, 30,500 injections were estimated to have been given in 2008 – a 150-fold increase in 10 years.

Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology, due to the presence of anatomical barriers. It was previously thought that drugs used to treat AMD such as Avastin and Lucentis have molecules that are simply too large to be effectively transported in an eye drop.

First author Dr Ben Davis (UCL Institute of Ophthalmology) added: "There is significant interest in the development of minimally invasive systems to deliver large drug molecules across biological barriers including the cornea of the eye.

"We have shown in experimental models a formulation system to get substances including Avastin across the barriers in the and transport them across the cells of the cornea. In theory, you could customise the technology for different drugs such as Lucentis, commonly used for AMD treatment in the UK, as it is a smaller molecule than Avastin so likely to be delivered effectively via this method.

"All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients – but the timescales are dependent on funding." The paper includes functional data showing that the avastin administered stops the blood vessels from leaking and forming new blood vessels, the basis for wet AMD.

This technology has been patented by UCL's technology transfer company UCL Business and the researchers are seeking commercial partners to accelerate development.

Explore further: Team finds potential topical treatment for macular degeneration

More information: The paper 'Topical Delivery of Avastin to the Posterior Segment of the Eye in vivo using Annexin A5-associated Liposomes' is published online in the journal Small, on Thursday 6 March 2014.

add to favorites email to friend print save as pdf

Related Stories

New drug could help AMD sufferers

Jun 18, 2013

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that ...

Cheaper AMD drug could lead to serious eye issues

Jun 18, 2012

A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.

FDA warns of another compounding pharmacy recall

Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

Recommended for you

Tissue regeneration using anti-inflammatory nanomolecules

20 hours ago

Anyone who has suffered an injury can probably remember the after-effects, including pain, swelling or redness. These are signs that the body is fighting back against the injury. When tissue in the body is damaged, biological ...

Cut flowers last longer with silver nanotechnology

Aug 21, 2014

Once cut and dunked in a vase of water, flowers are susceptible to bacterial growth that shortens the length of time one has to enjoy the blooms. A few silver nanoparticles sprinkled into the water, might be the answer to ...

Relaxing DNA strands by using nano-channels

Aug 20, 2014

A simple and effective way of unravelling the often tangled mass of DNA is to 'thread' the strand into a nano-channel. A study carried out with the participation of the International School for Advanced Studies ...

Сalculations with nanoscale smart particles

Aug 19, 2014

Researchers from the Institute of General Physics of the Russian Academy of Sciences, the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and MIPT have made an important step towards ...

User comments : 0